Uses
Cisplatin for injection is a platinum-based drug indicated for the treatment of: • Advanced testicular cancer. • Advanced ovarian cancer. • Advanced bladder cancer
Source: US FDA prescribing information
- Presentations
- 5
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Cisplatin is a platinum-based drug indicated for the treatment of advanced testicular cancer, among other approved uses. It is available as injection and powder for injection for intravenous use. MedsAcross supplies Cisplatin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Platinum-based Drug, Platinum-containing Compounds
- ATC classification
- L01XA01 Cisplatin · Platinum-based antineoplastic
- US FDA first approval
- 19 December 1978
- EU status
- Not recorded
- Orphan designation
- Not recorded
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Intravenous
- Dosage forms
- Injection, Powder for injection
- Identifiers
- UNII Q20Q21Q62JRxCUI 2555CAS 15663-27-1DrugBank DB00515Q412415
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
The main mechanism of the cytotoxic action involves the binding of cisplatin to genomic DNA in the cell nucleus to form interstrand and intrastrand cross-links. This interferes with normal transcription and/or DNA replication mechanisms and triggers cytotoxic processes that lead to cell death.
Source: US FDA prescribing information
Dosing overview
• Administer pre-treatment hydration and pre- and post-treatment antiemetics. • Cisplatin for injection has been administered intravenously at: o Advanced testicular cancer: 20 mg/m 2 daily for 5 days per cycle o Advanced ovarian cancer: 75 mg/m 2 to 100 mg/m 2 per cycle once every 3 to 4 weeks o Advanced bladder cancer: 50 mg/m 2 to 70 mg/m 2 intravenously per cycle once every 3 to 4 weeks. Refer to current treatment guidelines for specific dosing information. • Administer by slow intravenous infusion. Avoid contact of cisplatin for injection with aluminum parts.
Source: US FDA prescribing information
Contraindications
Cisplatin for injection is contraindicated in patients with severe hypersensitivity to cisplatin. Severe hypersensitivity to cisplatin
Source: US FDA prescribing information
Warnings and precautions
Boxed warning (nephrotoxicity, peripheral neuropathy, nausea and vomiting and myelosuppression. •): Nephrotoxicity: cisplatin for injection can cause severe renal toxicity, including acute renal failure. Severe renal toxicities are dose-related and cumulative. Ensure adequate hydration and monitor renal function and electrolytes. Consider dose reductions or alternative treatments in patients with renal impairment. • Hypersensitivity reactions: Anaphylaxis and death may occur, monitor for and treat accordingly. • Ototoxicity: Cumulative toxicity may be severe particularly in pediatric patients, consider audiometric and vestibular function monitoring. • Ocular toxicity: Optic neuritis, papilledema, and cortical blindness may occur. • Secondary leukemia: Secondary acute leukemia may occur. • Embryo-fetal toxicity: Can cause fetal harm.
Source: US FDA prescribing information
Side effects
The following adverse reactions are described in greater detail, in other sections: • Nephrotoxicity • Peripheral Neuropathy • Nausea and vomiting • Myelosuppression • Hypersensitivity reactions • Ototoxicity • Ocular toxicity • Secondary malignancies • Injection site reactions Common adverse reactions are nephrotoxicity, peripheral neuropathy, nausea and vomiting myelosuppression, and ototoxicity. The following adverse reactions have been identified from clinical trials or post-marketing surveillance.
Source: US FDA prescribing information
Interactions
The following drug interactions are described in other sections: • Nephrotoxic drugs • Ototoxic drugs
Source: US FDA prescribing information
Storage
Storage Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Prior to reconstitution, store in original carton to protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
5 presentations of Cisplatin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Cisplatin 50 mg/50 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Cisplatin 100 mg/100 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Cisplatin 200 mg/200 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Axycis 50 mg/50 mL injectionIntravenous | Avyxa Pharma | US FDA | Available on request |
| Cisplatin 50 mg powder for injectionIntravenousGeneric name | — | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 19 December 1978 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions
Conditions linked to Cisplatin in public data. This is not a list of approved uses, see the clinical information.
Amelanotic melanoma Bladder cancer Bone sarcoma Breast cancer Childhood cerebral astrocytoma Esophageal cancer Gastric adenocarcinoma Germ cell cancer Head and neck cancer Head and neck squamous cell carcinomaRare disease Hepatoblastoma Hodgkin's lymphoma, mixed cellularity Laryngeal cancer Lung benign neoplasm Lung oat cell carcinoma Lymphosarcoma Multiple myeloma Neuroblastoma Neuroblastoma, susceptibility toRare disease Non-small-cell lung carcinoma Osteosarcoma Ovarian cancer Prostate cancer Spindle cell sarcoma Stomach cancer Subependymal giant cell astrocytoma Testicular cancer Tongue squamous cell carcinoma Transitional cell carcinoma
Questions and answers
Is Cisplatin available for export from India?
Yes, on request. MedsAcross lists 5 presentations of Cisplatin and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Cisplatin have?
The catalogue lists 1 brand names for Cisplatin, including Axycis.
Is Cisplatin approved by the US FDA?
Yes. The US FDA first approved Cisplatin on 19 December 1978, according to Drugs@FDA.
Does Cisplatin need cold chain shipping?
No listed presentation of Cisplatin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Cisplatin in?
Cisplatin is classified under ATC code L01XA01 (Cisplatin).
References
- Cisplatin prescribing information (WG Critical Care). U.S. National Library of Medicine, DailyMed. Retrieved 24 June 2026
Request Cisplatin for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.